|
| Robust (n = 71) | Prefrail (n = 71) | Frail (n = 57) | P-value* | ||||||
| Current age (years), n (%) |
|
|
|
| ||||||
| [50 - 59] | 53 (74.65) | 40 (56.34) | 25 (43.86) | 0.001* | ||||||
| [60 - 69] | 17 (23.94) | 23 (32.39) | 19 (33.33) | |||||||
| ≥70 | 1 (1.41) | 8 (11.27) | 13 (22.81) | |||||||
| Age at ART inclusion (years) |
|
|
|
| ||||||
| <50 | 64 (90.14) | 50 (70.42) | 39 (68.42) | 0.002* | ||||||
| ≥50 | 7 (9.86) | 21 (29.58) | 18 (31.58) | |||||||
| Sex, n (%) |
|
|
|
| ||||||
| Women | 40 (56.34) | 51 (71.83) | 35 (61.4) | 0.15 | ||||||
| Men | 31 (43.66) | 20 (28.17) | 22 (38.6) | |||||||
| HIV profile, n (%) |
|
|
|
| ||||||
| 1 | 70 (98.6) | 61 (85.9) | 47 (82.46) | 0.007* | ||||||
| 2 | 1 (1.41) | 9 (12.7) | 8 (14.04) | |||||||
| 1 + 2 | - | 1 (1.41) | 2 (3.51) | |||||||
| Line of traitement, n (%) |
|
|
|
| ||||||
| First | 68 (95.77) | 68 (95.77) | 54 (94.74) | 0.93 | ||||||
| Second | 3 (4.23) | 3 (4.23) | 2 (3.51) | |||||||
| Third | - | - | 1 (1.75) | |||||||
| WHO stage OMS at inclusion |
|
|
|
| ||||||
| I | 20(28.17) | 22 (30.99) | 10 (17.54) | 0.27 | ||||||
| II | 22 (30.99) | 17 (23.94) | 14 (24.56) | |||||||
| III | 24 (33.8) | 27 (38.03) | 23 (40.35) | |||||||
| IV | 5 (7.04) | 5 (7.04) | 10 (17.54) | |||||||
| Nadir TCD4+ Lymphocyte counts (elements/mm3) |
|
|
|
| ||||||
| <200 | 41 (57.75) | 41 (57.75) | 29 (50.88) | 0.67 | ||||||
| ≥200 | 30 (42.25) | 30 (42.25) | 28 (4912) | |||||||
| Duration under ART (months) |
|
|
|
| ||||||
| <120 | 11 (15.49) | 13 (18.31) | 11 (19.3) | 0.34 | ||||||
| 120 - 240 | 55 (77.46) | 51 (71.83) | 36 (63.16) | |||||||
| >240 | 5 (7.04) | 7 (9.86) | 10 (17.54) | |||||||
| Current therapeutic regimen |
|
|
|
| ||||||
| Sans TDF | 3 (4.23) | 2 (2.82) | 1 (1.75) | 0.04* | ||||||
| Avec TDF | 68 (95.77) | 69 (97.18) | 56 (98.25) | |||||||
| Duration of TDF exposure |
|
|
|
| ||||||
| <10ans | 52 (73.24) | 55 (77.46) | 7 (12.28) | 0.001* | ||||||
| >10ans | 19 (26.76) | 16 (22.54) | 50 (87.72) |
| ||||||
| Current WHO stage |
|
|
|
| ||||||
| I | 70 (98.59) | 70 (98.59) | 54 (94.74) | 0.79 | ||||||
| II | 1 (1.41) | 1 (1.41) | 1 (1.75) | |||||||
| III | - | - | 1 (1.75) | |||||||
| IV | - | - | 1 (1.75) | |||||||
| Current viral load (copies/ml) |
|
|
|
| ||||||
| <40 | 71 (100) | 70 (98.59) | 55 (96.59) |
| ||||||
| >40 | - | 1 (1.41) | 2 (3.51) | |||||||
| Body mass index |
|
|
|
| ||||||
| Underweight | 5 (7.04) | 6 (8.45) | 8 (14.04) | 0.29 | ||||||
| Normal | 33 (46.48) | 27 (38.03) | 31 (54.39) | |||||||
| Overweight/obesity | 33 (46.48) | 38 (53.53) | 18 (31.58) | |||||||
| Sensory disorders |
|
|
|
| ||||||
| No | 71 (100) | 64 (90.14) | 47 (82.46) | 0.001* | ||||||
| Yes | - | 7 (9.86) | 10 (17.54) | |||||||
| Comorbidities |
|
|
|
| ||||||
| <1 | 45 (63.38) | 38 (53.52) | 35 (61.4) | 0.65 | ||||||
| 1 - 2 | 18 (25.35) | 19 (26.76) | 14 (24.55) | |||||||
| ≥3 | 8 (11.27) | 14 (19.72) | 8 (14.04) | |||||||
| Charlson comorbidity Index |
|
|
|
| ||||||
| <1 | 52 (73.24) | 44 (61.97) | 37 (64.91) | 0.69 | ||||||
| 1 - 2 | 11 (15.49) | 15 (21.13) | 11 (19.3) | |||||||
| ≥3 | 8 (11.27) | 12 (16.9) | 9 (15.79) | |||||||
| Polypharmacy |
|
|
|
| ||||||
| ≤4 | 58 (81.69) | 45 (63.38) | 34 (59.65) | 0.013* | ||||||
| ≥5 | 13 (18.31) | 26 (36.62) | 23 (40.35) | |||||||
| MNA |
|
|
|
| ||||||
| Normal | 63 (88.73) | 55 (77.46) | 16 (28.07) | 0.001* | ||||||
| Risk of malnutrition | 8 (11.27) | 16 (22.54) | 35 (61.40) | |||||||
| Malnourished | - | - | 6 (10.53) | |||||||